Max Planck Institute and Cellomics Announce Collaboration for High Content Screening Development
News Nov 02, 2005
The Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), located in Dresden, Germany, and Cellomics, a unit of Fisher Biosciences, recently announced a joint collaboration in the field of High Content Screening (HCS). The institute serves as a hub for numerous academic-industry collaborations in the field of HCS for drug discovery.
Cellomics provides a unique cell-based platform for its global clients in pharmaceutical, biotechnology, and academic institutions.
"We have always put a great effort in building bridges between academia and the industry," says Dr. Ivan C. Baines, Scientific Coordinator and Director of Services and Facilities at MPI-CBG.
"Working with a leader in a given technology provides unique opportunities to make new discoveries. Cellomics is a leader in high content screening instruments and applications - an area where we are very active having recently established a major assay development and screening facility. We anticipate a highly productive collaboration and are delighted to be working with Cellomics."
According to Daniel J. Calvo, President of Cellomics, the collaboration objectives include a mix of applications and new product development, as well as establishing a key demonstration center for Europe. "Max Planck is a perfect partner for us," stated Calvo.
"They have tremendous experience and capabilities in this area and their strong ties to key academic centers across Europe are a real plus. This collaboration will provide valuable input to help drive the development of our product and applications portfolio for the growing academic market."
As part of the Agreement, MPI-MCBG has purchased the Cellomics' ArrayScan® VTI HCS Reader along with its complete portfolio of BioApplications and HCi™ informatics software.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018